Brokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $4.80

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $4.80.

Several research firms recently issued reports on KPTI. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price objective on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Robert W. Baird decreased their target price on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Finally, StockNews.com raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th.

Karyopharm Therapeutics Trading Up 1.9 %

Shares of KPTI stock opened at $0.87 on Friday. Karyopharm Therapeutics has a 1-year low of $0.62 and a 1-year high of $1.95. The stock has a market cap of $108.43 million, a price-to-earnings ratio of -0.69 and a beta of 0.20. The stock has a 50-day moving average of $0.79 and a 200-day moving average of $0.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analyst estimates of $36.07 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KPTI. AQR Capital Management LLC increased its holdings in shares of Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock valued at $649,000 after acquiring an additional 622,194 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at $494,000. Ikarian Capital LLC increased its stake in Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Karyopharm Therapeutics by 34.9% during the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after buying an additional 56,613 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at $167,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).